Charity number: 1135319 Company number: 07003983 British Society For Paediatric Endocrinology alld Diabet£8 (A company limited by Euarantee) Trustees, annual report and fmancial statements for the year ended 31 August 2025 Brltlsh Soelety For Paediatric Endocrinology Hnd DiAbetes (A eompany limited by guarantee) Contents Page E£8al and admijjistrative itrformation TTUStee%' gnttual report 2.12 Indcp¢Tthnt BKamirters' rcp)r¢ 13 StateJneDt of financial activities 14 Bajance slwl 15-16 Notes to the statements 17-22 British Society For Paediatrie Endocrinology Dlabetes (A eompany Ilmlted by guarantee) Lcgal and administrative infomation Charity reELgtratlon number 1135319 Company registrotion number 07003983 Business addws elo Fiona Rega 6 Sherboutnc Wsjk Fan)h&m Common SL2 3TZ Registered offJ¢t 69 Carter IAne IA)ndon EC4V 5HF DT Fiontt Reg2n, Treasurer Dr Tabitha R￿Id¢ll (resigned 9 Oclob¢r 2024) Dr Melanie Kershaw Ireyigned 9 Oclober 2024) Dr Talat NQushtaq, Ch8iTman (appginled 9 O¢¢ober 20241 Dr sentb1lku￿ar Karuppallan8ellDi&ppan.lappointed 9 October 20241 Secretary Accollntsnts i£ftley Rowe & Compsny Second Floor 87- 88 Turtitnill Street LondoD ECIM SQU Bankers Lloyds BankPIc Kings Heath 32- 34 AIcc51er Road South Kings Heath Bit]ningha]n B147PU Page I British Society For Paediatric Endocrinology And Diabetes (A company liinited by guarantee) Report of the trustees, (incorporating the directors, report) for the year ended 31 August 2025 ThE trustec5 prG*nt Ihcir rcport and the financiaI slatcrllcnts of Ihc charity for thB cndcd 3E AuEUSt 2025. The trustees have adopted the provisions of the State]Dent of R¢commended Practice (SORP) Accoullting and Reporting by Charities, {FRS 1021 in PT¢pJring the annual Teptsil al￿ fittancial siaieinellls of thL' charity. The d5Tectors of the charstable coInpany are Lts trusleBS for the purposes of charily law. The directors who served during the year and up to the date tsf this i¢port aTe set ollt ort page l. Structhrei govtrnÈnet #nd mAnhgement The Brili8h Society For Paediatri¢ Lndocrinolo8y and Diabrtcs t.% ¢on.%tiruitd by a Deed of Trust and ￿S a registetrd ctLarity No 1155319. The charity chattged il% Ststus 10 a company limited by guaraDtee from 01 September 2010. ObJectlv&s and ae¢ivltles The ainL% of the charity are to advance education in paediatii¢ 6ndocrinology and iylated $llbjects by pmmoiing research and disscrnit￿tlng the useful results of such r¢searth. In keeping with thB aillts. Ihe Socitty shall have thc follow&ng power5= To arrange aJ)d provide for the holding of mcetings. Icclures and seminars. 2. To procure to be writt¢n and print, publish, i55u¢ and circulate gratuitously or othenvise such paperss periodical%, pamphlets or other docuTThents. 3. To ittise funds and to invite a[￿ ieceivE corttributions from any person or per.80r15 whaL%oever by Wdy of 5llbgcriptiong and OthE￿j￿￿ piovided that Ihc Society shall not undertakc any ￿r￿a￿Tht trading activities irt rèisirt8 Mnds for its primary charitablc objectives. 4. To coopErate, as¥OGiate or &ifiliaie with any other charildble institutions. 5. To do all such other lawful things a5 are necessaTy foi th¢ attain]nent of the above objectives. Thc charity 474 TllBTnbBrs, who inLlude doctors. scientists. 211ied profe5sioDals {5peciaJist Durses, phsnnacists Ènd dieiitian5) aftd medical sNdent%. During 2024-2025. the Sociely has been actsve in pre5enljD8 clinical and basic research Én the field trfpaedialric Cndocrinology and diabetes. both to it5 own tn¢mbBts and the wider pacdiatric community. Members of the 8OCtety are reprcsented on Con￿￿1￿CeS With othcr related societi&% to ensure close liatson, alld paediatlic endocrillology rcprcscntation in the dtawing up of ¥uAdelines. Examples include NICE, European Endocrine Refeienre Nelwork (Endo ERN), EuTOPEan Network of Paediattic RtsedrLh ai the European Medicines Agency (Enpr-EMAI, Diabetes UK, CYP Diabetes Board. Socicty for Endocrinology and ACDC. The charity works elosely with natiollal agenGies for paedi#tyi¢s and is 2ffJliaied with the Royal College of PaediatTiCS and Child H¢alth, BTltish Endocrine Si)ciBty. Ruyal Culltge of Physicians aThd the Society for Elldocrinology. Th¢ Society also woiks closely with Paticnl Support Group8. such as Th¢ Child Growrh Foundatiort, 'fhc 'I'urner Society Support Group. Briiish Th)Yoid Foundation. Pituitary Foundation and Living with CAH. Page 2 British Society For Paedi#triL Endocrinolo&v And Diabete8 (A company Ilmited by guarantee) Report of the trnstees, (incorporating the direetors, report) for the year ended 31 August 2025 Major areas of 3¢tivity in support of these objectives In 2025 we held our aT￿U￿1 ￿￿tIllg in Sheffi¢ld. It was well utt¢nded and d¢lav¢Tcd ¢Xc¢ll￿¢ 8cA¢ntsfic progra]ntne witlj a wide range of tOPiC5 ¢oveTing the depth and bTeadth af pdediattic endocrinology and diabetes delivered by r¢nowned speaker%, including many local delegatcs f￿[n the adult and patdiatric cndocrirtt community. BSI)ED 2025 Aw8rds Session was held on the second day of the n]ccting in which thc Plcnary talk by the Jamcs M Tanner Award winner was delivered by Dr JeKmy Allgrove, delailing h]'s journey throughout his C4T¢¢r. DrA]IgTUV¢'5 work iu the arena of ¢alciurn and bune enducrinology has significantly contFibuled to paediatric endoctinology and he has a syndrome bE4TiJ)g hi5 narnE due to hi5 J]ov¢I WQTk for that syndrome. Other highlights included o Expert taikslsymposia {x 6) delivered by cxpert speakers o Parallel endocrinology and diab¢te5 5¢3siDn5 Pei¥onaJ Practice sessiuD aryd 4 Saiellite Symposia Preseniations from previous ycarfs BSPED Award winncrs o BSPED 2025 Awards Session Top 8coring absltacts as ora] collllnunicatlOll5 Guided poster totsrs o CME day including interesting case proscntalions Nurse and Endocrine Profe85iona]s Session o How do E7 sessions {¢ndocTin¢ & diabEt¢51 Page 3 British Society For Puediatrlc Endocrlnology And Diabetes (A company limited by guarantee) Report of the trustees, (Ineorporating the directors, report) for the year ended 31 August 2025 Key &ctiwty 2024-2025 Virtual Paed5atrie Endocrinc Group (VPEGI Managed by Renuka Dias as POC Chair and supporied by Dinesh Giti as CME OfFicer PopulaF quarterly p￿SC￿lation scssions with up lo 70 pcDple rcgistcring for the meetings in 2(r24 Awards and grdnts Overse¢n by th¢ Awards Con]tniltee'. Charlotte Eldcr {Chair), Executiv¢ Cotntnittee m¢tnbers and Ctini¢a] Con]mitt¢e ChaiT Cutr¢Tht Gjanls and aWaTd5 Research & InnovEuon Award Pae(ftatric Endocrine & Diabeles Nurse & AHP Awards Jaffles M Tannu Award {NorninatsoD5 for 2026 hav¢ b¢¢n ¢nleTed a wituw Selected by a judging panel) CoDf¢Ten¢¢ Travel Grants Peer Rtvicw BSPED now ntllDing a virtual peer review proces8 with a numl)erof reviews tsking place in 2025 itlcludsng Kings C'.ollege 14ospilal uj lJ)ndon and Alder Hey in Live￿001. Support for LSLIU ma%t¢rs covrse for nur￿5 BSPBD funded 10 Nurses in 2024 to complete this nutse endocrine masiers mLNlule NHSE Out-patient Recovery and Transfor￿all0￿ Prograttulle BSPF.D Chair represented RCPCII on programme RCPCH- BSPED been woTking closely with theffl otheT project5 Pkediatric Endocrine Nurse Cotnpeiency framework- BSPED funded & f8ce-lo-face meeting io gei an 8Ereed nauonal competency frattJework for paediatric endocrine nwse8 New special interest wDup set up to look at Pre-diabeles and p085ibl¢ trealmcnL4 to delay on%et of Type I diab¢le8 Growth Study Day- a facs-to-fac¢ Tneeling focusing on growth was fvnded and run by the wwth $petial inteTe$t gtDUP Grant and Project fvlldillg for 2026 and beyond BSPED now actÉv¢ly Seeking id¢a5 and suggegtitkns frtsTn its rneTnbers for ptojtcLs to ￿nd irt coming years. The key ctileria foT gitty Ptoje¢t is thoL il wuuld btitig benefit io BSPED and the widerEttdecrine Cotnmunity Mejnbersbip Fees in 2025 BSPED fees increased in 2024 $0 left at £126 per year for 2025 Royal College of Paediatiics and Child Health Annual Professional Meeting 2025 24th May- Face to face BSPED special interest group syniposLUln Combined session with British Paediatiic and Adol¢sceRt Bone Group 4 gllest speakers and 5 OTal cornmutticaii0tt8 0 41 abstracts submitted: 4 oral presentations at the symposiuD]. 35 as ePoster5 Page 4 British Society Foi. Paediatric Endocrinology Diabetes (A eompAny Ilmited by guarantee) Report of the trustees, (incorporating the directors, report) for the yellr ended 31 August 2025 Summary of Cllnlcal Committee Activity 2024-25 Ke Activities Guidelin¢, 5tandatds pusilion sialemenls St[eaD￿l￿e pmccss for review of clinical ￿lIdelIne & 5talldards Updated.. hornjonc 8upplem¢ntstion for pvb¢rtaI induciion in girls {July 2025)- use of GnRH anajogue shkred care {Seplember 2025), Non-SIG gutputs NH.8E laboratory handling of insulin reque515 111 th¢ hand]irtg of irtvesiigation of hypoglycaemia UK achundroplasia managem¢nt guideline Isubmilted rot publication) UK endo bone munitoting of vatDomlonc for DhqD including managcmcnt of Hdretlal supprtssion during switching from cla%%ic CS Ipubli%hed on WwW.dn￿¢arc￿k.or8I IJK bone ma￿￿eMent of adults with DMD inGluding transiliort Ibeittg written for publication. laullch oJ)]ine clinician webinar cfhursday 22nd January 4-5 pTrl Survc TuTner Syndron% UK service evaluatiotl Survey {¢liniciatL and pa¢i¢rttl Survey oft access to technology for CYP with diabetes known to social carc. NICE consultation Consultsiion on the use of Teplizumab and drth guida]]C6 Overweight alld obe81ty quality standards Vasorotid¢ usc forachondropla5i4 Patient infomjaiion upd&ie Evorel patch use DUAVP deficiency Pros and cons of Gl4 (Grtsllrth SIGI CAIS IDSD SIG} Other5 NHSE CYP gender serylce %pecificEtuort Neonato18nd p&ediatric ph8rnJaey group INPPGI steroid p05ilion sthtetneni NICE At guideline Paediatric Adrcnal In5uffi¢icn¢y steroid card translation ArAbi¢, Grvk, Polish, Rom2nian. SlovaL Turkish. Urdu, MandariTL BSPED Paediatric ERdocrine Nurse SpeciHiist Competency Developmental Framework (Pctcr Laing. KaT¢n Thompwnl Ongoing BSPED working gr()up Oll Standards of ¢ducatiort oFpaediatric adrenal insufficicllcy Ongoing {infO￿￿ed by rtur%e survey. survey & focus group of parcnls and CYP via (lelphi con8en8lls} FuudLDg from Addisons Disea8e Self Help Group, Living with CAH PtNitary Foul￿ation lo eo4evelop (involving care-givers and CYP} nalional information sheet Page 5 Brltlsh Soeiety For Paediatric Endocrinology and Diabetes (A company limited by guarantee) Report of the trustees, (incorporating the directors, report) for the year ended 31 August 2025 Focus for the coming year12025-261 Guidance on devcloprnent of BSPED paticnt information leaflcts BSPED AI steroid card translation F￿uLatIonal standatds Df paediatric At Educational vidEQ5 on sick day managcmcnt of AI Steroid card INPPG li8ise wÈth &drcnal SIGI Consider NtCE Al guideline (input froln adrrnal SIGI Update guid¢lines including sex $teToid priffling guideline S eeial Interest Grou Special Interest Groups Growth Disorders Helell SiorE Thyroid Catherine P¢lersrfimCbeetha]n DSD 2ainaba MohaTned CAII ladrengl Nils Kione {R2thi PT&8ad) HPAT Paul DimitrilHoong Wei T2DM Pooja SachdevlEvelien gevers Pr¢-TIDM Tabitha liandelVRachel B¢5ser Ro5earch Indi B4n4]iee 2025-2029 2020.2028 2020- 2028 2016- 2025 2021-2028 2019- 2025 2019-2027 2025-2029 l. Growth Disorders Main outpuis {2024-251 Electronic Browtji chartproject.. nalional audit IIOO+ Cent￿5) and ynter-software acuwacy testing progressed with RCPCH collaboration D¢veloping nati(Inil guidante on adjbnct gTowth thetapies IGnRHa, aromaiase inhibiiorsl. Developin8 ttational Euidance onTall Stattue I)￿agement. tklivered national education day- Focus on Growth.. Growth DisoTd¢rs in Childhood (London, 4 July 20251 with B8Pr￿, Kindustry %upport Updated BSPED clinical r¢sour¢es'. PIS on pr0￿cOnS of hGH: $h8redoare guidattce forhGH: guidanee for LAGH usehnonitorittg. En2dgement & liaison.. NICE ILAGH, hGH for Noonanl. BNF¢ Isomatotropin 5e¢li0Ths), NHSE Genotnic Laboratory Hubs {gene panels). Generation% Study Cl. StTengthen¢d train¢¢ involvement and secutrd BSPED Ex¢¢ sllpport for pllblications from projects {tr8ineu as ftyst authors). Focus for the coming year (2025-261 Complete submit snanusci7pts: (l) Electronic ¢hgrt aUd1V￿f0rn￿1¢¢ (target.. Arehives of Disease in Childhotyl, with RCPCH)'.12) Adjunci therapies review Itgr8ei'. European lourllal of Endocrillology}: (31 Tall Stature guidance to BSPED CEiniLdl Collllniltee. Plan two further national educ&tion days., initial thcnK'. "Growth os5e55En¢iit forp￿m￿ ¢are" (20261 with BSPllD gTant support. Develop new workstreaJJ)s'. Growth monitoring posi(IOtt S12temeni- 2)ational IGF l assay audit & SDS calcuJ&tor' conttibulc to GlobE ReB rare wwth disorder projects. Hold a dcdicatcd sc55ion at the Natiollal Mceting to sct 2026 TC%¢?tchleduc&ti()n prioritiL% 2nd refjne SIG strategy. De¢p¢ll collalx)tatiOn5 With RCPCH {r¢ptrs¢ntstion on con]tDitleeslw()rksng grollps} artd ￿ntInue ]iaison wiib NICEIBNFtlNHSE Genomics. P8ge 6 British Society For Paediatric Endocrinology and Diabetes (A company limited by guarantee) Report of the trustees, (incoryorating the directors, report) ror the year ended 31 August 2025 2. Thyroid Main output$ {2n24-2025) Iniiial service evaluation across 4 terti￿Y c¢tLtres with res¢aT¢h ethics in plaGe,' final Manuscri￿ iij preparaiion. Opumised outcotne data proLesse5 foi primary CHT with the Newboin Screening Iaboralory. National ques1ionnBir¢5 to newbDtn 12b& 2nd B.gPED Tcgional cDmtnittecs on CHT data collcclion. findings pre5entcd at thc national newlxTrm lab scientific meetjJJE. A¥reed thanEe io the CHf algorithjn as ￿qUested by Newlx>Tn ScKEning Laboratori¢s. Colldboiation wilh Generation R to evaluale thyroid gene panels. Expert illput lo Brili4h Thyroid FoundaliDn patient irtFoTmation resources. Shared Ksearch theme.% with the BSPED Research SIG. Focus for the upcoming year12025-20261 Work willi BSPF.D regional networks to itnprov¢ PTiTn4ry C.H'f ouicnmtt d&ta ctslletliott. Advocatc with natioJ]al newborn.stteetting br)dies for a unified UK datsba￿ for oUtCon￿ data. CoTnple¢e and bubtnil the cetttral CFrr nwJu8cripi. Assess feasibility and proslcons of s¢reetLillg foT seGond8ry (central) CHT IA the UK. Supw>rt, publicisc and faeilitale recruitment to the NIIIR fund¢d GT¥vey' Rcf (lead.. Wood). 3. DSD Main outyuts (2024_25) R¢-audit of BSPBD DSD Standards completed., manuscript in preparation: publication funding seL'UTed via BSPBD (2025). Education & professional devcloptllcnt rclaunclLBd.' quarterly ra5¢-b#5ed di$cus%ion me￿$￿£s. New rcscarch updatcs shared r¢gu18rly Quality ITnpTov¢rnenl.. DSD animation vtdeo (BCHI completed and published Updated BSPBD CAIS p&tiLni inlormalloti leaflet. Engagement & &dvocacy'. promoted SDM projects,. contributed lo national di8¢US$iOttS Ojh Sports participation amd Icgavcthical dcvelopni¢nts (¢.g., April 2025 Supreme C()urt ruling). Coffltnunily & ¢v¢nls'. aciive participation around l DSD SymposiumacLivities IStockholTn 2024). Foc￿* for the cotning year12025-26) Prioritise Quality InwTovementprojects to updateil DSD staodords 8nd future publication& Develop & share refery￿ and transilion p2tbw2y& from 14rger cetttres to support national alignment. Expand patient education resotsrccs {addititsnai videos and updalcd leaflets) with Charsty partner3 {DSD FaThilics). C041evelop inlcrim position statement on sports participation in youllg peopl¢ wth DSD with Genomics colleagues: issue joint statement. Establish a service evaluation u¢rci5el¢ool via 2 focus gmup attd pilot across centres. Contir)ue hotizon scanning and farilitatd debaie on leg8Veihtcal implication5 le.g-* %POrt, April 2025 ruliILg, boKing & DSD routtdl8ble follow upl. Plan for international collaboration aDd repr￿ent￿tIon ahead of the 12th 1 DSD Symposium (L¢lbeck, 1-3 July 2026). Page 7 British Soclety For Paediatric Endocrinology and Diabetes (A eompany Ilmiled by guarantee) Report of the trustees, (fincorporating the directors, report) for the year ended 31 August 2025 4. Adr¢naVCAH Main outpuis (2024-25) Advanced collection & #naly5is of ieai WOTld dala on CAH cate across the UK & Irelartd. Oral ￿ld poster pie5entations delivered at BSPED and ESPE mecting8. Initiatcd planning for & face 10 face SIG day meeting with industry engagcmcnt. DixLus8ed NI￿ Euidance on adrena] insufflciency. Launched projecl strands on rare adrenal insufficiency and adrenal tUmOUTS. Fwus for th¢ coming year12025-261 Cunlirtue long ienn real world CAH data pro￿. develop benchmaFking across centre¥. Deliver invesligdloi. inilialed irial (sub51anlial funding secured., Pl.. N. Krone, U]uversily of SheffiEld). Produce guidance for raTC adTcnal condition% lincl. raTt Al and lldrcnal hJmour%). Progrcss plan5 for a ll01ittn&l flltt ￿ face meeiing to sh8re d&ill. siandards and rese8rch priorities. tudenhip tratssillolj to Dr Rath Prdsad and refresh membership engagenKnL 5. HPAT Mail) ouiputs12024-25) RcEular national & inlemalional HPAT casc di5CU85ions {cotnpl¢K HPAT ts]mQUT5). Active roles in SIUP Brain TuTnour gT<>UPS {CraniopharyrtgiotM. Low Gr8de Glioma) &nd SIE ECOL project (endocrine conditions over the lifecouTse). Publications adv￿]ng the field.. Hyob reviews. MEKIBRAF inhibitorendocrine toxicitie5,' OPGIIGF l abDorma]itie$ {multi centre eollab()rationsl. Indu8try-clinical collthotHtion with Rhythm Ph8rma¢ellii¢o1s to $upport access to setmelanotide for hypothalamic obesity {HyOb). C]inical trials.. TRANSCEND Isetmelanotide) phase Ill RCT completed with excellent PTimW Out￿M¢(920% BMI reduction ovcrall.. 920.2% in childrcn): Bivarnclagon phase 11 oral M(XR &goni5t in OLE phAse with allajyses urtdenvay. Education.. contributLOn5 to SIOPe BTG education thiy BPNA trainees, education. ottgoing moDtb]y knowledge shaTing MDT. Focus for the coming year121r25-261 SustaiTrmonthly natiollavinlernational HPAT MDT me¢ting5. G¢n¢rate further publications OD identificaiion 2nd managemetti of HPA fUn￿UrS. Establish and mDbilist an Optic Pathway Glioma I IGF I registry,. resolve logistlC5 at AGM. Work with Rhythm Pharni8ceuticals to secure UK aeccsslapproval for sctmclanotidc in Hyob. Ensurc UK ccntrcs arc rcady atld participating in forthcoming Hyob tri￿S (¢.g.. GLP I I dextroamphetatnine). Run the 2nd National HPAT cOnf￿¢ll¢¢ and di5seminaLe besi prattice. Publish HPAT service outcotne% and support ECOL lifecoursc cttdocrine work8tr¢am%. Progress pthcipation in international reBistrie8 Icraniopharyngioma: Hyob stud2es with NLf£UriGh￿¢nm0rk). 6. Typ¢ 2 Diabete$ Maill outpuls12024-25) D¢Jivered 2 national o]JliDB s￿dY days IDec 2024.. Jul 2025). Est2blishtd iegional HCP pecr-stspptsrt neiworks with regularupdales to the national group. Pllblishe(Vupdaied tools.. Fir81 Ye8r of C8re Pathway. Individual HCaIthca￿ Plan for schools. Developed palielll information lea(Aels on medi¢atsoD5 with DigiBete¥ protJ]uted tith T2D modules. Supported YoungTypB2 DigiB¢l¢ resource5 and input to NPDA Spotli8htT2 work. Page 8 British Society For Paediatrie Endocrinology and Diabetes (A company limited by guarantee) Report of the trustees, (incorporating the direetOTS' report) for the year ended 31 August 2025 Focus for the corning year (2025-26) Cuntinue tWAce-yearly nationa] study days dnd strengthen regional peer DetWOTks. Publish revised ACDC guidance medicatiun lek(leislresDuiLes for familieslHCPs. Pilol a face-10-faee training sesslon on r2 servAce good practice ond spread learning. Run nationa] survey on CGM use and admission at diagnosis. review NPDA Spotlight extended analysis when avttilable. Sllstain First Year of Care ilnplementation and update resources based on feedback. 7. Pi£-TIDM Main outputs12024-25) SIG expanded to include wider MDT and transitioDJadlll( di2betes representation across the UK. UK Pre TID pathway finalised. accepted for publication in Diabetic Medicine (July 2025, open ac¢es5). UK HCP survey on managing Pre TID completed- published in Diabelic Medicine (May 2025). AlldÉt standard8 ag]Ecd to monitor cornpli¥nce with uulcomes from the BSPED Pre TID pathway. Joini initia(ive with Sanofi to create regional Pre TID clinical chaTnpions (0.25 PAlweek for 12 ￿onthS) across all UK networks., interviews held Sept 2025. Initiated Collaboration discussions with Sanofi & ABCD on feassbility of screening first degree Telatives of CYP with TID for alltoantibodies. Focus for the coming year (2025-26) Produce educational videos for HCPS on Pre TID management and screening. Develop family facing resources wÉth DigiBete. Establish and support regional clinical chatnpions- coordinate pathway audit activities. CollecL national audit data on CYP with Pre TID per the BSPED pathway. Promote and collaborate with the UK Islet Autoantibody Registry. Contribute to discussiuns on emerging disease modifying therapies to delaylprevent TID. Contribuie to discussions on wider population screening and to any proposed NICE guidance on TID scrcening and trcatnients. Ensure the Pre TID pathway is easily WC￿8]b]e on the BSPED website. 8. Research Main outpllts {2024-2025) 3 meetings held and group established (transition from NJHR ClÉnical Studies Group). Aimslobje¢tives defined; leadership stTUCtllre identified. Member survey launched to manage expectations (analysis pending). Supported collaboration incl. NIHR-￿RdCd rnlllticentre ritUXiIniib trial. Supported national grani applications from BSPED centre8. Trainee developTnent activities initiated. Focus for the coming year (2025-2026) Discuss operation as an independent R&s¢arch Committee with BSPED Exec Sup￿)rt. Enable collaborative, multi-centre grant applications. Provide peer review for applications and study do8igns. Develop infrastructure to support resident doctors in paediatiic endocrinology resear¢h. Evolve visionlaims with new coordinatorlchair and deputies. Pv&ge g British Society FOY Paediatric Endocrinology and Diabetes (A eompany limited by guar8ntee) Report of the trustees, (incorporating the direetors, report) for the year ended 31 August 2025 Streamtining develupNnenl of BSPED stalida￿S giiidelines Guidance on develDpJnBnt of BSPED paticnt information leaflets B.8PBD AI 8temid card trllnsl8tion5 o Educalioj￿l standards of pacdiatric Al Google Analytics to review website engaBe]nent BSPliD Lirjkedln presence Conlrihutitsn8 its key NICE consultations.. Teplizumab. Irview of Al guidan¢e, ¢t¢ o Re-l&unch of GH Audit Holling peer review proce5S o Reviewing 8IGs and terms of T¢f¢rence Audits WoJl( on n]odcrnising th¢ growth hornione audit continued in 2024 witb the help of a grallt froJn Merrk Serono with a platl to reb¢#rt in 2025. BSPED Website Development The websRte is aimed at: Pioviding up-to4aie usef¥l & relevani informalion to en¢ourag¢ u5agt of the si16 by hEalth proftssionals as well as patientslcarcrs Facilitsting cottllnunication & collaboration amo]J¥ BSPBD members Piornoting QUT specialty grtd sotiety nauottally at)d internationally Providing a user friendly e.g. smart phonc friendly veTSlOtI P4ge 111 Brltish Soclety For Paeditstrie Endocrinology and Diabetes (A company limlted by guarantee) Report of the trusteo8' (incorporating the direetors, report) for the year ended 31 August 2025 Other supported aelivities The Socieiy Supported a nvmb¢t of other 4¢tivits¢S in 2024-2025 which included: Funded Masiers iiursinB Courses in Paediairic ￿)do¢rAnD[02y, tA)ndDn Southbat￿ University (£12,850) Travel and attcndancc grant% for junior mcmber% prescnting their research work at annual cottfercnces to the sum of £3.716 Educational prizes / research awards £28,800 Grant given io host a nati(>tt growth study day £lO.O(XI Endocrinc nurse colllpetency framework development work Spunsurs There 15 dedicat￿ financial support to thc SocÉety frortb %ponsors from the pharniaceulical industy. In 2tr25 the partnership. sponsorship snd engagement optK>rtuniLies were exp&ndEd tn include a vaTiety of diffe¥eDI syNnp05ia and workstations. ltell￿ throughout the year available for purch&se inclllde Enember webinarlenJaiVLewsletter adv¢rtisinglsection of the partner resource library. AnniiaI mcetings opportunitics include salcllilc 6yjnpos1un￿Bx￿ibl1Orrt0nyard logold¢lcgate bag logo. The majority of the sponsored funding is to support thc Annua] Meeting. growth hortTh)tte &udiL research Erant educa¢iotVdl training s¢55ion5 for doctors and nurse5. SOMB of the funding is used for Ctinical con￿7111ee, Executive Commiitee Clinic21 Speciat Inierest Grollp aaivities. Funding atso contributes lo the running of the Society al￿ Secrelari&t fees. Flnanelal revlew It is the policy of the Sijciety to maintain u]]restricled fund$, whi¢h ar¢ the fr¢¢ r¢5¢rves of the clwity. The rc5¢rves ar¢ held al a level that ensures the fijmre fin8ttcia] viability of Ihc.8ociety. That level is deeTned to bB on¢ that equate5 to a of approxitnatcEy three y&qrs' expenditure. Note L4 of the ftnancial sli)tements indicates that there 8re £1,077,993 unrestricted fvud5 a5 at 31 August 2ff15. Thi5 provides sufficient funds to COV￿ ￿aftagement. administration and support costs. PAge 11 Brilisl) Si)ciety Fvr PuLYliatric Endocrinoltsgy I)label¢s IA comp8ny limited bs, gu¥rant￿) Reyvrl the. tl'lTSte£%' lineoryDi#ll*g the d5rECtrfJ￿, reporti f(>r the yeur c￿ded 31 August 2025 blDl¢mcnt ot. ts'uSl￿S, i¢sportfibllÉtfies 'I'he INtlte¢ IN. Tc%piTrn%iblc for prLpurin¥. th¥ TnJ%tees' Aiiiiual Rl'port JDd itse finincial ¥lr?Icnitrnr_s in qccorddnLC with vvIiL'51bli uiid UDilb¥J KingdoiD Geii¥rnJl)' Ac¢¢pi¢d Ac.cftiintinE Pr.Ittitc C.i)NiputJv l￿W tL'4uire% the IN$iees 10 prepare rjn￿￿]ll1 swlem¥n15 for Vi4 ch [￿11￿cl￿1 V¥41r whiili gLVL li und fair VIL'IV Ot the staitr ol iffairs uf ihL' ch>itil¥blL& L'tiri)Pdny ￿nd o* IhL jlllOIIIII28 fesourtt% and application c>f fL%iiiifcL'%. inLludimLI IhL' inLnniL expendiluie, ol the chaniable compiiny lor that prriod. In prLTArinLT ihL¥L liniincial $14iiemenls, die Irusieeg re(IllAietl iu-. IiLiL'% and IIILll Eiyyly th¢Jii iotlfl.%l¢Trrly: ebserve lh¢ m¢lhod.% and priA¢iple% tbt ChTrriiltY SOIiP: iiitskL judgcitJL'IILS dijd esiiniaies thli i Jre reJson4ble and prudi Trt.. stilt* ivhelheT LippIjLdible IJK. A￿lI￿Nting stand￿d% huve b¢¥n tollowed. 5ubjeLt tu arLy ￿llen￿l dep£iriute¥ disLlo8ed aiid explained in Ih¢ fu)JnLial sidiemeni8', and prepdTe the finJnL'ial %laltnitni.% ott IhL g.oin8 concern ba%is up1¢5s il ?¥ jt)l* PPTOPrilltc to PTr.yutnc thol the ¢huiifjble company ￿111 conlinui in Dperation. The Iru8tee8 are rcsp¢Msiblc for kecpinb. proper JcLoUnlln￿ tL'L'nnl* wh2clI disLlose wlih ietssonable ￿LUr￿LY at Rny limL Ihc IiiiJiiLial pnsilion of th¥. ¢huriiable compJAy and which enabk them In ¢p¥uru Ih:Il ihc finJiicilll slolemenl% ¥MTrmplywith rhe C(¥mp:wies Act 21K16. Th¥y llTLW JL%u res&￿￿11b]e foi sale%uaiLIiiJ8 the ilS5els of tht Lharilijble LiwDpuny dnd hLIILL foi. iea50nable %t¢Ds for the ptL4velltion and dL'tErtion of frMiJ(5 <)th¥'r im'pular&lits. Small pr•vi$iiiA Thiy ieyolt ho5 b¢¢n Pl¢P¥ir¢d in aLcordallLf wiih the 4iecial Pro￿41￿n¥ ftlj. LxJfiip'iJhlLg under Pdrt IS ut. IhL CliTnPdlllL'4 ALI 2(1116. Thi5 fCPOrt approi'ed by ihe Board f)n ?9 JuDe 20?6'.1Tr11 ¥ibincd lip il¥ hLhJifby Dr Fiona Heg3n Tr￿s￿r¢r Pb¥e IZ Brit15h Society fior P&ediatric Endocrinology and Diabetes (A company limited by guarantee) Independent examiner's report to the trustees on the unaudited fillanci81 statements of British Society For Paediatric Endocrinology and Diabetes. I retM)rt lo the charity iDJste¢s on my exanunalion of the finatjtial ¥ialem¢nls of Britssh Society For Pacdiatric F.ndocrinoloBy alld Diabetes for the y¢arended 31 August 2025 set out on pages 12 tD 22. Responsibilities and basis of report As tILe ¢harity trustees of the wmpany (3nd al%0 it5 directois for the putpo%es of company law) you are responsible for the pKparation of the finanGial 51atemettis io #t¢ord8rtce with the requirements of the Companies Act 20061'the 2￿6 Act'l. H&vittE s&iisfied myself th2( the financial statements ofihe company arc not required to be audited under Part 16 of the 2006 Act and are eligible for ittdcpcndcnt cxatjiinalion, I report in respect of niy examination of YOUT ¢Otnpany'$ zttounts as carried out uttdcr scction 145 of the Charities Act 2011 I'tht 2011 Act). Tn caTrying out Tny examirtaiiotj I have followed th6 directions given by the Ch3tiiy Commission uttder section 145(5)(bl of the 2011 Aci. Independent examTner'5 Statement Since the compaDy'% gro%.8 incotne exceeded ￿50,000 your examinet mugt be a memberof 2 body lislcd in section 145 of Ihc 2011 Act. I confim that l am qualified to ￿ndCrtake the examination because I8m a mcmber of thc Institulc of Challet¢d Ac¢ountartt$ ith Ettg]and And Wales. which is one of the listed bodi&8. I have compleied tny examination. I Conf￿1￿ that tLO t2)alter8 have to my attention in tot￿tE10n with the examination giving me cause to beli¢v¢ Ihal ill any Jnat¢Tial Kspect.. accountiog records were not kept in accordance with section 386 of the Co]Dpanies A¢¢ 21M)6: or 2. the financial stateTn¢nts do not a¢¢ord with such records. or 3. the fillancia5 statcmcn18 do not comply with r¢lev8nt a¢¢ounting r¢quiremenEs under section 396 of the co￿par￿l¢s A¢t 2006 otheT th￿ pthy re4uiretneDt Ihat the fJnanciaI statements give a'true and fair, view which is not a n]atter consid￿Ed ab parl Of an indepenenl examinaiioji,. or 4. the financial slatemellts have not bcen prcpared in accordance with the methods and pri￿lpleS of the Siatctn¢nt of RecotntD¢nd¢d PtHclice foT awounung ieportin8 by ch8riti&%. I have rto concerns and have come across no othcr matters in conncclion with th¢ exaTninatinn to which attentiots.%hr)uld be drawtl this report in order to enable a proper understanding of the fin0n¢ial statemetsts fo be reached. Christopher ACA Independent examiner Leftley Rowc & Company Chartered Accountants and Ststulory Auditort s￿nd Floor 87- 88 Turnmill Street London ECIM SQU 29 June 2026 Page 13 British Society For Paediatric Endocrinology and Diabetes (A company liti]ited by guarantee) Statement or rinancial activities (incorporating the income and expenditure account) For the year ended 31 August 2025 Unrestrleted fllnds 2025 TotAI 2024 Total Note5 Income Incoming re50urLes from geneTRting fi]nds.' Activities toi generating funds Income from investmenis 362,306 16,742 362.306 16.742 372.064 21,462 Total income 379,048 379,048 393.526 Expendlture Co8ls of generating fvnd%: Cost oFgeneratill8 fi]Rds Expendits]￿ on charitable aEtsvities Othcr 81,692 ¥76.917 -5,841 81,692 276.917 5.841 65,947 269,236 6,89.5 Totsl expenditu 364.450 364.450 342,078 Net movement In funds 14,598 14.598 51,448 Reconciliation of fuDd5 Total funds brought fonvard 1,063,395 1,063,395 1,011,947 Total funds carrled forward 1.077,993 1,077,993 1,063,395 The slatetnent nf financial aclivitiL4 includes all gain% 2nd losses in the year and thcrcforc a 8eparatc statement of total cognised 8aitt$ snd losses has not been preparcd. All of the abDve attK>unts relate lo conltnuing activiti&%. The notos on pages 17 to 22 tntegr&l part or these nnandRI ststements. Page 14 British Society fior PaediatrAe Rndocrinology 2nd Diabetes (A company lin)ited by guarantee) Balance sheet as at 31 August 2025 2025 2024 Currwjt 8&sets Debiors Cash at bank and in haT 37,081 1,058,880 1.0611.652 1,101,288 1,095,961 Creditors: #mollnts fallln due within one year 12 123,295) (32.566) Ntt current assets 1,077.993 1.063 J95 Net assets 1,077.993 I,(KS,395 ChyTlty Funds Unrestricted fi]nds 14 1.077.993 1,063 J95 Total funds 1.077.993 1,¢kn3.395 The BaSaJ)c¢ Sket contirtues ort Ihe following page. Th¢ notes on pages 17 to 22 forni an integr81 part of Ihese finan¢lal statements. Page 15 Rritish 5oLiety Fvr P#ediatric Enducrinology And Di*bÈtts IA Lompany limlied hy %uaramteei BHIDn¢e.%lieet Icoiililluedl Trustees slthtemettLs rcqu5rnd hy Llie LoIhpanies Ael 2006 foi. the year eIided 31 Auxuyl 2025 appiDviThb) ￿￿.$1. li￿111L7￿l.I￿1Il.￿]L'rklts trll.4itt% 5)f rhL' e'trendtd J l ?025. I l ) en¥iiriI>b Ihii I Ihe ¢OlliPiiliy kc'L'PS prvpLI JLLVuiilin￿V TLLVtd¥ whirh L(>inplv wilh 5CLlion .l¥b ol Ihc C.nMipini¢¥ A¢1 )OIKI, Ihe IiD3nLllal and of ils sufplvs oi. d¥fi¥il fui tlkL IhL'n L.￿d￿d in aLcTrrdqMLt Il'lLb th¢ reriiiirLineniK ttlseiElQJ)s_194 and.391. ¢inO (¥'hich ¢ihp.r¥vise iomply wlih Élio piKIFi&i0115 of Ili¢ Cuiiipu¥ii¢s AL'I SLX16 rLldiin&p It) finanL1￿1 %tstrm¢ntq, go JppltedblL 10 ihL' i'ompJn> 'IIK'%L IinJnEitsl.*iaieineTrl¥.'IrL' prepilN.d jii •liionlancL' wilh IhL bPL*itsI p4iJvi¥iviib Ill 15 v( IliL' CvrnpaTJiLA￿ Acl ?IllJfi t¢lalinx lu srnall cnThpJDie>. The fi￿9￿101 slnl¢incB15 i%eTr 7￿ VPLVYL'a bv IIJL. l)uJrd (in ?l) JunL' 21))h.'Ind ils bchall b> Dr Fiuud Regan reasureT.'fnLSt¢c Reglstratjoll nwmber 07￿￿3y¥5 Thr OSL pales 17 ID 2zfvrm inltwdl part ofih¢sr finaDciaJ stgtethtttts. Pagc 10 ritish Society For Paediatiic Endocrinolo￿ and Diabetes (A company limited by gllar&ntee) Notes to financial statements for the year ended 31 Au¥ust 2025 Accounting policies The ptincipal dc¢ouuting PDlicies gre sumrtiarised below. The aceountiIJg poltcies have b¢¢n applied tonsistenily tl)roughoui the yw and the precedinE year. 1.1. Basis of Jecounting The fitknlnLial SLiteillents hdve bcen prcparcd accordance with AcwuDtsng and repDrting by Chatitie8.' Statcmejjt of Rccommended Practice applicablc to Gharit1¢5 prOpa￿Trg thcii 2tcouni* irt accordance wilh thc Financial Reporting Standard app1￿cable in th¢ UK and Republic of IreIand (FRS 102} leffectivc l January 2015) Icharili¢b SORP IFRS 102)), the Financial Reporting Slandard applicable in the UK and Republic of Ireland IbR.S 1021 and the Ch￿il￿eS Aci 2011. Btili.sh Society For P8ediatric Endocrinology and Diab¢t¢s meets the definitiOD of 8 public benefit enuty undcr FRS 102. Assets and liabilities are initially ttcognised ai histOriC41 cost or transactioD value unless othcThvis¢ Stated in the relevant 8ccounting policy nDielb}. The t[uSt￿ consider that therc are no n￿terIal unccrtainitiC5 about thc TtU5t'6 ability to ¢onittsue as a going concern. For the reporting year tlic charity has updated the presentatlott Df some of its categories of income and ¢xp¢nditut¢ so a$ to httter refltct 11$ current operation8. Where relevant the cornparative amounts h8v¢ #l¥0 beert y￿gne1[ tts this preseniauon. This has had no impact on the reported sutplus or nEt asset ptssiiiotj for the currellt or tomparauvc year. The fJrtmcia] slatemcnts arc prcscntcd in steTling whith 15 th¢ fvtriionol currency of the Charity. 1.2. Cashflow The charity has iakeo advantage of the exemption in FRS102 from the reqllirejnent to produce a cashfiow stalement becau8¢ it is a STnall charity. 1.3. Incoming resource All incoming resOUrt&4 Are intluded in the statement of financial activities when the ch2llty 18 entit]ed to the income and the amount can be quantified with reasonablc accur&cy. The followin¥ speLific w>licies are applied to particular ca*gories of income: Voluntary incomc is re￿ived by way of grants, donations and gifts and is included in full in the slat¢rnCiLt of flnancial activitie% whrn Tcceivabl¢. Grnnt$ where entitlcment is not conditional on the delI￿ry of & spe¢ifi¢ rfoimon¢¢ by th¢ chariiy. sre recognised wheTh the charity becom¢5 UtLconditionaJly ¢ntitl¢d to th¢ W. Donated scrvices and facilities are included at the value to the charity where this can bc quantified. The value of services providcd by voluntecr5 has Dot been intluded. Gifts dojmted for resale are included as illcotning resol￿￿5 within activities for ge]xerating hjnds when they are sold. InComcfro￿ lTLV¢stfft￿tS is 5ncluded in thc yeAr in which itis receivable. PAge 17 British Society For Paediatrlc Endocrlnology and Diabetes (A company limited by guArantee) Notes to financilll statements for the year ended 31 August 2025 1.4. Resources expended Expelldiiure is recogllised on an accrual b&518 X5 a liabilily 1$ iftctstred. Expendiwre includes any VAT which callnot be fully recovered, and is r¢pvrted as part of the expettdittjre 10 which il relAles. Costs of generating fvnds cornpri￿ thc costs a550ciat¢d with #ttracting voluttt8ry income and the costs of trading for fundraising purposes including the charity's shop. Charitable expenditwe comptises tho%c tosts incurred by th¢ charity in th¢ d6livcTy of Als &ctiviiics tnd Service8 for it5 ￿￿tricI£￿e%. It includes both cost8 that can bc allocated directly to such a¢iivities and tlM>se cosis of ittdireci namre necessary to support them. Support costs are those costs incurred directly in suppori of cxpcnditurc on the objects of the Charity and include projccl manag¢men(. 1.5. Leasing Assci.q obiained under htre purchase contracts and finance leuse5 yre L#Pi(uiised as tangible assels and depreciated over the sliorler of ihe lease term and their usefvl Itves. Obligations under such Agreem¢nts are included in creditors net of the fjnance charge allocaied lo future periods. The finance eleTnent of the r¢ntal p)yment 1$ Charged to the profil Ènd lo%s account so as to producc coll5tant periodic rates of ¢h8rge on the net obligauon8 outstanding in eachperiod. Activities for Renerating funds Unrestricted run418 2025 Total 2024 Total Sponsor Ineome Membership Sub5criplitsns Annual Meeting tncome 53,445 59,160 269.701 53.445 39,160 269,701 108.5(K> 48.665 214,899 362,306 362.306 372,064 frvln investments Unrestrlcted fundb. 2025 2024 Tot91 Bat￿ Inte￿5t receivabls 16,742 16.742 21.462 L6,742 16.742 21.462 Page 18 British Soelety For Paediatric Endocrinology and DiabetQ8 (A company limited by guarantee) Notes to financlal statemenL for the year ended 31 August 2025 C￿￿1 of generatin% fwids UnrestrlLted fun05 2025 Tol•l 2024 Total Secretariat fee5 Wcbsiie expenditure SporLsof CQTtllnissioft Credit card ch4Tgc5 Sllndry expenses 53,249 11.159 14.027 53,249 11,159 14.027 46,978 10,642 5.550 3.257 3,257 1,133 81,692 81,692 65.947 Expenditure on choritsble activltles- by fund type Unr>rictcd funds 2025 Total 2024 Tot41 Annual meetitlg Traitting Resca￿h 217.417 1.5(K) 58,0(K) 217,417 1.500 58.000 220.086 15.8.$0 33.300 276,917 276,917 269,236 Expenditure on charitable activities. by activity A¢Uvltles ndvrtrake dlrectly GrAnt fllndlng adivitle5 Support tosts 2025 Tolal 2024 Total A[￿Ual meeting Tratning Rcsearch 212,356 3,800 15,850 33.300 1,261 217,417 1,51X) 58.OIK) 220.086 15,850 33,300 212,356 52.950 1.261 276,917 269,236 Page 19 Brit15h Soclety For Paediatrle Endocrinology and Diabetes (A eompany limited by guarantee) Notes to fJnanelal.statemenLs for the year ended 31 August 2025 Other Unrestricted funds 2025 ToiAI 2024 To121 Accountancy- monthly bookkeeping Acc(iuntancy- yearly financial %talernen15 In5UTan¢e Bank char8e8 3,564 1268 3,504 2,268 3.366 2,268 1,186 75 5,841 5.841 6,895 Analysis of support eosts Annual meeting 2025 lotal 2024 Total Travcl expettses 1,261 1.261 177 1,261 1,261 177 Employees There w￿e no employees duiitlg the yeAr. No salarie5 or wages have been p93d io the tnjstees dwing the ye￿. io. T￿ation The charity's activities fa]1 withitt the exemptions affi)rdcd by the pmvisions of Part 10 Encomc Tax Act 2007 or Section 256 of thc T8xation of Chargcable Gains A¢t 1992 10 the extent that these are applied ￿ Its charitable objeels. Accordingly. there 15 llo taxativn ¢hotge itt these accounts. ii. Debtors 2025 2024 Other debio PrepaynKnts accrucd income 24.636 8,(X>O 25,975 11.106 32.636 37,081 Pw20 British.¢iociety For Paediatrie Endocrjnology and Dlabetes (A company limited by guarantee) Note.￿ to fInancial statements for the year ended 31 August 2025 12. CreditOTS: amounts falling due Ivitlthi one year 2025 2024 AccNals and dcfcrred income 23.295 32,5f 13. Analysis of net assets between funds Ul￿trIcted Total Futld balances at 31 Augu8t2025 ￿ t¢P1¢5enied by.. CllrreJJt assct8 Current liabiJiti¢s 1,101,288 (23.295) 1.101,288 123.295) 1,077,993 1.077,993 14. Unrestricted funds At 31 AuEllSt 2025 Oponlng Incomlfjg Olllgoffing fund5 resources resources General rcscrves 1.063.395 379,048 {364,4501 1,077.993 Purposes of ullrestricted funds The purpose of the unrcstriclcd funds is to advancc cducatio]J in paediatric endo¢tinology and r¢l#ted subje¢ts by promoting research and disseminating the u8tful rebulib ofsu¢h rese2rcb. 15. Restricted fund5 At 31 Au8Wt 2025 Op¢nlng fund5 Restricted fwids Page 21 British Society For Paediatric EndoLTinology DiAbetes (A Lompany limited by guarantee) Ni)te,4 to financi#l ststemcnts ror the year ended 31 August 2025 16. Company limited by guarantee Briiith Socieiy For Paediatric End(￿illo10gY and Diabet¢8 is a cornpatly limited by guaTanlee and accordingly does noi have a 8hgJe capital. Bvery membeT of ihe compaDy undertgkes io contribut¢ such amolltti gs may be required not exceeding £1 to the assets of the charitable compaiiy in rhe eveni of its being wound up while he or she is a member, or within one year after he or she cea8¢5 to be a Jnember. Pag¢ 22